Literature DB >> 27270773

Reply to "Uveal melanoma cells are resistant to EZH2 inhibition regardless of BAP1 status".

Lindsay M LaFave1,2, Wendy Béguelin3, Richard Koche4,5, Matt Teater3, Barbara Spitzer1,6, Alan Chramiec4, Efthymia Papalexi1, Matthew D Keller1, Todd Hricik1, Katerina Konstantinoff1, Jean-Baptiste Micol1, Benjamin Durham1, Sarah K Knutson7, John E Campbell7, Gil Blum8,9, Xinxu Shi10, Emma H Doud11, Andrei V Krivtsov4, Young Rock Chung1, Inna Khodos12, Elisa de Stanchina12, Ouathek Ouerfelli10, Prasad S Adusumilli13, Paul M Thomas11, Neil L Kelleher11, Minkui Luo8, Heike Keilhack7, Omar Abdel-Wahab1,14, Ari Melnick3, Scott A Armstrong4,5,6, Ross L Levine1,4,14.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27270773     DOI: 10.1038/nm.4094

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  8 in total

1.  Frequent mutation of BAP1 in metastasizing uveal melanomas.

Authors:  J William Harbour; Michael D Onken; Elisha D O Roberson; Shenghui Duan; Li Cao; Lori A Worley; M Laurin Council; Katie A Matatall; Cynthia Helms; Anne M Bowcock
Journal:  Science       Date:  2010-11-04       Impact factor: 47.728

2.  Uveal melanoma cells are resistant to EZH2 inhibition regardless of BAP1 status.

Authors:  Marie Schoumacher; Stéphanie Le Corre; Alexandre Houy; Eskeatnaf Mulugeta; Marc-Henri Stern; Sergio Roman-Roman; Raphaël Margueron
Journal:  Nat Med       Date:  2016-06-07       Impact factor: 53.440

3.  BET inhibitor resistance emerges from leukaemia stem cells.

Authors:  Chun Yew Fong; Omer Gilan; Enid Y N Lam; Alan F Rubin; Sarah Ftouni; Dean Tyler; Kym Stanley; Devbarna Sinha; Paul Yeh; Jessica Morison; George Giotopoulos; Dave Lugo; Philip Jeffrey; Stanley Chun-Wei Lee; Christopher Carpenter; Richard Gregory; Robert G Ramsay; Steven W Lane; Omar Abdel-Wahab; Tony Kouzarides; Ricky W Johnstone; Sarah-Jane Dawson; Brian J P Huntly; Rab K Prinjha; Anthony T Papenfuss; Mark A Dawson
Journal:  Nature       Date:  2015-09-14       Impact factor: 49.962

Review 4.  Targeting EZH2 in cancer.

Authors:  Kimberly H Kim; Charles W M Roberts
Journal:  Nat Med       Date:  2016-02       Impact factor: 53.440

5.  SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2.

Authors:  Kimberly H Kim; Woojin Kim; Thomas P Howard; Francisca Vazquez; Aviad Tsherniak; Jennifer N Wu; Weishan Wang; Jeffrey R Haswell; Loren D Walensky; William C Hahn; Stuart H Orkin; Charles W M Roberts
Journal:  Nat Med       Date:  2015-11-09       Impact factor: 53.440

6.  EPZ011989, A Potent, Orally-Available EZH2 Inhibitor with Robust in Vivo Activity.

Authors:  John E Campbell; Kevin W Kuntz; Sarah K Knutson; Natalie M Warholic; Heike Keilhack; Tim J Wigle; Alejandra Raimondi; Christine R Klaus; Nathalie Rioux; Akira Yokoi; Satoshi Kawano; Yukinori Minoshima; Hyeong-Wook Choi; Margaret Porter Scott; Nigel J Waters; Jesse J Smith; Richard Chesworth; Mikel P Moyer; Robert A Copeland
Journal:  ACS Med Chem Lett       Date:  2015-03-04       Impact factor: 4.345

7.  Loss of BAP1 function leads to EZH2-dependent transformation.

Authors:  Lindsay M LaFave; Wendy Béguelin; Richard Koche; Matt Teater; Barbara Spitzer; Alan Chramiec; Efthymia Papalexi; Matthew D Keller; Todd Hricik; Katerina Konstantinoff; Jean-Baptiste Micol; Benjamin Durham; Sarah K Knutson; John E Campbell; Gil Blum; Xinxu Shi; Emma H Doud; Andrei V Krivtsov; Young Rock Chung; Inna Khodos; Elisa de Stanchina; Ouathek Ouerfelli; Prasad S Adusumilli; Paul M Thomas; Neil L Kelleher; Minkui Luo; Heike Keilhack; Omar Abdel-Wahab; Ari Melnick; Scott A Armstrong; Ross L Levine
Journal:  Nat Med       Date:  2015-10-05       Impact factor: 53.440

8.  BAP1 deficiency causes loss of melanocytic cell identity in uveal melanoma.

Authors:  Katie A Matatall; Olga A Agapova; Michael D Onken; Lori A Worley; Anne M Bowcock; J William Harbour
Journal:  BMC Cancer       Date:  2013-08-05       Impact factor: 4.430

  8 in total
  3 in total

Review 1.  BAP1 mutations in high-grade meningioma: implications for patient care.

Authors:  Ganesh M Shankar; Sandro Santagata
Journal:  Neuro Oncol       Date:  2017-10-19       Impact factor: 12.300

2.  Resetting the epigenetic balance of Polycomb and COMPASS function at enhancers for cancer therapy.

Authors:  Lu Wang; Zibo Zhao; Patrick A Ozark; Damiano Fantini; Stacy A Marshall; Emily J Rendleman; Kira A Cozzolino; Nundia Louis; Xingyao He; Marc A Morgan; Yoh-Hei Takahashi; Clayton K Collings; Edwin R Smith; Panagiotis Ntziachristos; Jeffrey N Savas; Lihua Zou; Rintaro Hashizume; Joshua J Meeks; Ali Shilatifard
Journal:  Nat Med       Date:  2018-05-21       Impact factor: 53.440

Review 3.  Epigenetics of hematopoiesis and hematological malignancies.

Authors:  Deqing Hu; Ali Shilatifard
Journal:  Genes Dev       Date:  2016-09-15       Impact factor: 11.361

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.